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Reply to the Editor." 
My colleagues and I thank Drs. Sakakibara nd Mitsui 
for their interest in our work and for raising the important 
question of the effluent return to the systemic irculation. 
Undoubtedly, the venous effluent of limbs reperfused 
after several hours of complete ischemia contains greater 
amounts of myoglobin, free hemoglobin, creatine kinase, 
and potassium than do control limbs. After complete 
ischemia, this has been shown in experimental 1 and 
clinical 2studies. To a lesser degree, this increase was also 
measurable after revascularization for incomplete isch- 
emia. 3
These components in the venous effluent are a conse- 
quence of the severe local damage of skeletal muscle 
(rhabdomyolysis, edema) and are the cause for systemic 
complications (hyperkalemia, myoglobinemia, cute renal 
failure, acidosis, multiorgan failure, and death) following 
revascularization after prolonged periods of  limb isch- 
emia. 
Our limb reperfusion strategy has been developed to 
decrease the skeletal muscle reperfusion injury after re- 
vascularizations for prolonged ischemia. Less local dam- 
age will result in reduced concentrations of potassium, 
creatine kinase, and hydrogen ions in the venous effluent, 
which could be demonstrated in an experimental study. 1
Nevertheless, the venous effluent, even after controlled 
limb reperfusion, still contains ignificant amounts of end 
products of the rhabdomyolysis, which can only be pre- 
vented from entering the systemic irculation by discard- 
ing the venous effluent. Simply discarding the venous 
effluent is not possible because of the large amount of 
blood that would be lost. The same is true for any filtering 
process. The only possibility is to separately cannulate the 
femoral arteries and veins and use an extracorporeal 
circulation including oxygenat0r and roller pumps. This 
approach was recently described by Vogt and coworkers 2 
from the Zfirich group in a patient with complete ischemia 
for 24 hours. 
The concentrations of myoglobin, potassium, and crea- 
tine kinase in the venous effluent are related to the 
severity of ischemia (complete/incomplete) (1/3) and the 
duration of ischemia (2/4). The more severe the ischemic 
insult, the more pronounced is the reperfusion damage, 
resulting in higher concentrations in the venous effluent. 
In our three-center study, 4 we were able to reduce the 
concentrations of myoglobin, potassium, and creatine 
kinase to a level that did not produce systemic hyperka- 
lemia or renal failure. However, Vogt and coworkers 2 
have used a complete xtracorporeal circuit (including an 
oxygenator) for a patient with complete ischemia for 24 
hours and achieved excellent results with this approach. In 
patients with complete ischemia exceeding 24 to 36 hours, 
it might very well be necessary to discard the venous 
effluent and use an extracorporeal circuit to prevent 
severe systemic side effects. In our study with a mean 
ischemic time of 26 hours (range 6 to 39 hours), we did see 
systemic increases in potassium, creatine kinase, creati- 
nine, and blood urea nitrogen; however, this did not 
produce remote organ failure. Even though we did not 
measure myoglobin concentrations in our patients, the 
fact that none had severe renal failure shows that there 
was no major renal tubular dysfunction. 
Ideally, future refinements in the technique of con- 
trolled limb reperfusion will elucidate criteria, identify 
which patients will need controlled limb reperfusion with- 
out complete xtracorporeal circulation, and define those 
patients who need controlled reperfusion with venous 
effluent discardment. 
Friedhelm Beyersdorf, MD 
Department of Cardiovascular Surgery 
Albert-Ludwigs- Universitiit Freiburg 
79106 Freiburg, Germany 
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Failure of devices used for the closure of atrial 
septal defects 
To the Editor." 
I read with interest he report of Agarwal, Ghosh, and 
Mittal 1 on the surgical management of unsuccessful atrial 
septal defect (ASD) closures with the AngelWings device 
(Microventa Corp., White-Bear Lake, Minn.). These clo- 
sures were performed by me as a part of the International 
ASD Closure Trial, which is being organized by the 
University of Minnesota to evaluate the feasibility, safety, 
and efficacy of a new percutaneous device 2 developed at 
the University of Minnesota. Our preliminary clinical 
experience in the first 100 patients (including the six 
reported by Agarwa!, Ghosh, and Mittal 1) has been 
submitted for publication. The overall procedural success 
rate is 90%. We have learned a large number of lessons in 
the clinical use of this device from the more than 100 
patients who have undergone this procedure. 
The reason for emergency surgery for retrieval of errant 
devices has been the difficulty in retrieving the device, 
which is made of a nitinol alloy framework with a high 
tensile strength. Although we have demonstrated our 
ability to retrieve the device with snares in animal mod- 
els, a the stiff wire can potentially perforate cardiac ham- 
bers and systemic veins. The overriding concern in the 
clinical trials has been that of patient safety and hence the 
adoption of a policy of surgical removal of unsuccessfully 
deployed evices and closure of defects. We have concur- 
rently developed a system for retrieving these devices 
safely. Once this is made available to participating centers, 
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the procedural success rate will be much higher than at 
present and the need for emergency surgery minimized. 
In these initial cases, we l used device sizes twice the 
balloon-sized diameter. 2 With experience, we have deter- 
mined that we can successfully use ratios between 1.2 and 
1.5, and, so long as the conjoint suture ring diameter 2 is as 
large as the anatomic diameter of the ASD, residual 
shunts are uncommon. The transient complete heart block 
(which did not require temporary pacing) was probably 
related to the large-sized evice used. 
Percutaneous closure of ASDs in human beings, who 
have thin compliant atrial septa and great variability of the 
size and position of the defects, is more difficult than the 
closure of experimentally created circular defects in the 
thick muscular atrial septa of dogs. 2 This device is self- 
centering and hence the anatomic riteria for selection of 
suitable candidates for this device is being actively inves- 
tigated. 
Surgical closure is the "gold standard" for the closure of 
ASDs. All three patients who needed emergency surgery 
in the series reported by Agarwal, Ghosh, and Mittal 1 
were adults. In a surgical series of 166 adult patients with 
ASDs, Horvath and associates 3 reported an early mortal- 
ity rate of only 1.2% but a perioperative complication rate 
of 13%. The complications included arrhythmias necessi- 
tating cardioversion, reoperation for bleeding, air embo- 
lism, tamponade, congestive heart failure, cerebrovascular 
accident, transient ischemic attack, complete heart block, 
and respiratory failure. Obviously these two reports can- 
not be directly compared. In the next phase of the U.S. 
arm of the trials we will be formally comparing device 
closure and surgical closure in patients with identical entry 
criteria. 
We hope that with greater experience in the use of this 
device, careful ong-term follow-up, and comparison with 
surgical closure in a structured clinical trial, we will be 
able to determine the role of this new investigational 
device for the percutaneous closure of ASDs. 
Gladwin S. Das, MD 
Cardiovascular Division 
University of Minnesota Hospital and Clinic 
Minneapolis, MN 55455 
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Reply to the Editor." 
The response of Dr. Das has aptly focused on the 
current deficiencies of atrial septal defect (ASD) closure 
devices and the limitations of extrapolating data from 
animal trials to therapeutic use in human beings. It was in 
this perspective that we proposed the currently relevant 
indications for the use of ASD closure devices. We shall 
not play Nostradamus. When Dr. Das's newer trial with a 
lower device/defect ratio and new retrieval system be- 
comes reproducibly effective, it may change the therapeu- 
tic approach to closure of ASDs. 
Probal K. Ghosh, MCh, FRCSE 
Surendra K. Agarwal, MCh 
Pramod K. Mittal, MCh 
Department of Cardiovascular and Thoracic Surgery 
Sanjay Gandhi PG Institute of Medical Science 
Lucknow 226 014, India 
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Purulent pericarditis 
To the Editor: 
We are very interested in the article by Mann-Segal and 
associates, 1 concerning successful treatment of purulent 
pericarditis by irrigation of fibrinolytics, and we fully 
support his technique. We 2 previously reported the use of 
intrapericardial urokinase to dissolve pericardial fibrin 
layers in three patients, and the drug was well tolerated in 
these patients. Mann-Segal did not mention laboratory 
tests in his report; in our patients no changes occurred 
either in hemodynamic or in coagulation parameters 
during the period of intrapericardial fibrinolytic therapy. 
Our safety measures included echocardiography during 
instillation to detect iatrogenic right heart compression 
and warming of the irrigation fluid to prevent arrhythmias. 
We used urokinase for the lysis of pericardial fibrin 
deposits because urokinase has equal fibrinolytic potency 
but less antigenic potency than streptokinase. 3 The effi- 
cacy of urokinase in dissolving extravascular fibrin has 
been demonstrated especially in the pleural cavity by 
intrapleural administrationJ '5 
Fibrinolytic pericardial irrigation with urokinase as well 
as streptokinase seems to be a promising treatment of 
exudative fibrinous pericarditis, which can prevent con- 
strictive pericarditis without surgical intervention. The 
ideal dose and treatment regimen, however, remain to be 
defined. 
W.-B. Winkler, MD 
R. Karnik, MD 
Z Slany, MD 
Department of Internal Medicine II 
Krankenanstalt Rudolfstiftung 
A-1030 Wien, Austria 
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